SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.49
+5.11%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +29.7%
- EBIT
- -29.6%
- EPS
- +34.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +88.1%
- EPS
- +5.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +10.3%
- Net income
- +13.0%
- EPS
- +50.0%
- Free cash flow
- +19.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026